Bioaxia Life Sciences Fund LP
Raised
Pre-open
Investors
—
Min Invest
$500,000
AltStreet Analysis
·Generated from EDGAR primary sources
Bioaxia Life Sciences Fund LP is a Delaware-domiciled pooled investment fund filing under Rule 506(b) and Section 3(c), managed by Bioaxia Life Sciences Fund GP LLC and Bioaxia LLC with Douglas Eby as an executive officer. The filing is pre-open with no capital raised or investor count disclosed. The minimum investment is $500,000.
This is a private life sciences fund utilizing the standard 506(b) / 3(c) exemption structure typical of institutional alternative investment vehicles. The $500K minimum investment positions it at the lower end of institutional or high-net-worth qualified purchaser funds, accessible to accredited investors rather than exclusively institutional capital.
Data Flags
EDGAR Filing Data
Form D — Primary Source
View on SEC.govRelated Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
n/a Bioaxia Life Sciences Fund GP LLC
Executive Officer, Promoter · New York, NY
n/a Bioaxia LLC
Executive Officer, Promoter · New York, NY
Douglas Eby
Executive Officer · New York, NY
Is this your offering?
Claim this profile to add contact information, team members, LinkedIn profiles, fund history, and additional financial data. EDGAR-sourced data and AltStreet analysis cannot be edited, but corrections can be requested for verifiable inaccuracies.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.